I-Chow Hsu

I-Chow Hsu is a faculty member in the Department of Radiation Oncology at the University of California San Francisco (UCSF), School of Medicine. He is actively engaged in clinical research and treatment innovation, particularly in brachytherapy and radiation oncology for genitourinary and gynecologic cancers.

Education:

• BS in Biochemistry, University of Florida, 1987 (Magna cum Laude)
• MD, Johns Hopkins School of Medicine, 1991
• Internship, San Bernardino County Medical Center, 1991–1992
• Residency, Columbia-Presbyterian Medical Center, 1992–1995

His research interests span radiation oncology, brachytherapy, prostate cancer, gynecologic cancers, and radiotherapy planning. He focuses on high-dose-rate (HDR) brachytherapy, salvage treatments, toxicity management in complex patients, and improving access to radiotherapy in low-resource settings. His work integrates advanced imaging, treatment planning, and clinical outcomes analysis.

The recent publications (2020–2024) reflect a strong emphasis on clinical safety, treatment efficacy, and innovative planning techniques in brachytherapy and external beam radiotherapy. Topics include HDR brachytherapy for prostate and gynecologic cancers, reirradiation strategies, and automation in treatment planning. The research spans from single-institution analyses to international consensus studies, highlighting collaborative and translational impact.

Scientific Awards and Honors:

• Alpha Epsilon Delta Medical Honor Society, 1987
• University of Florida BS, Magna cum Laude, 1987
• Dean's Fund for Research, Johns Hopkins, 1988
• John Scott McFarland Fund, Johns Hopkins, 1989
• Accolade for Outstanding Intern, San Bernardino County Hospital, 1991

Dr. Hsu has contributed to significant clinical trials, including long-term results from NRG Oncology/RTOG 0321, and mentors junior researchers and residents through collaborative publications. His work involves grants and institutional support, particularly in advancing brachytherapy techniques and global oncology applications. He is affiliated with multidisciplinary teams in radiation oncology, medical physics, and gynecologic and urologic oncology, contributing to both clinical care and technological innovation in cancer therapy.